Cessatech A/S (NGM:CESSA)

Market Cap	271.48M -10.3%
Revenue (ttm)	6.57M +20.0%
Net Income	-14.44M
EPS	-0.78
Shares Out	18.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,888
Open	10.00
Previous Close	9.98
Day's Range	9.60 - 10.10
52-Week Range	5.50 - 26.00
Beta	0.51
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Cessatech

Cessatech A/S, a pivotal-stage pediatric biotech company, develops specialty hospital medicines for children in Denmark. Its lead candidate product is CT001, a fixed-dose nasal spray for treating acute pain in children. The company also develops CT002, a non-invasive intranasal sedation for children undergoing medical procedures in Phase 2 clinical trials; and CT003, a topical anesthetic in pre-clinical development. The company has a collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of m...

• Industry: Pharmaceutical Preparations
• Founded: 2020
• Employees: 3
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: CESSA

Financial Performance

In 2025, Cessatech's revenue was 5.72 million, an increase of 130.01% compared to the previous year's 2.49 million. Losses were -10.90 million, -25.67% less than in 2024.

Financial numbers in DKK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 15, 2026

Data Sources Report a data error